Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Eric Gumpricht, Isagenix International, LLC, United States

*CORRESPONDENCE Jestin Thomas ⊠ jestin@leadsbio.com

RECEIVED 06 May 2024 ACCEPTED 20 May 2024 PUBLISHED 04 June 2024

CITATION

Roopashree N, Syam DS, Krishnakumar IM, Mala KN, Fleenor BS and Thomas J (2024) Corrigendum: A natural sustained-intestinal release formulation of red chili pepper extracted capsaicinoids (Capsifen®) safely modulates energy balance and endurance performance: a randomized, double-blind, placebo-controlled study. *Front. Nutr.* 11:1428397.

doi: 10.3389/fnut.2024.1428397

COPYRIGHT

© 2024 Roopashree, Syam, Krishnakumar, Mala, Fleenor and Thomas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Corrigendum: A natural sustained-intestinal release formulation of red chili pepper extracted capsaicinoids (Capsifen[®]) safely modulates energy balance and endurance performance: a randomized, double-blind, placebo-controlled study

N. Roopashree¹, Das S. Syam², I. M. Krishnakumar², K. N. Mala³, Bradley S. Fleenor⁴ and Jestin Thomas⁵*

¹BGS Global Institute of Medical Sciences, Bangalore, Karnataka, India, ²Akay Natural Ingredients Ltd, Kochi, Kerala, India, ³Sri Rama Hospital, Bangalore, Karnataka, India, ⁴DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Harrogate, TN, United States, ⁵Leads Clinical Research and Bio Services Private Limited, Bangalore, Karnataka, India

KEYWORDS

capsaicin, thermogenesis, Capsifen, endurance, energy expenditure, FenuMat, respiratory quotient

A corrigendum on

A natural sustained-intestinal release formulation of red chili pepper extracted capsaicinoids (Capsifen[®]) safely modulates energy balance and endurance performance: a randomized, double-blind, placebo-controlled study

by Roopashree, N., Syam, D. S., Krishnakumar, I. M., Mala, K. N., Fleenor, B. S., and Thomas, J. (2024). *Front. Nutr.* 11:1348328. doi: 10.3389/fnut.2024.1348328

In the published article, there was an error in Figures 3A, C, 5B as published. In Figure 3A, there was an error in representation (second and third inset of Figure 3A were interchanged), but it was correctly mentioned in the results section. In Figure 3C, significance was marked wrongly in CapF 100 even though there is no significance. In Figure 5B, the percentage difference provided was wrong and the correct values were mentioned in results section. The corrected Figures 3A, C, 5B and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



FIGURE 3

Violin plot showing the acute and chronic effects of CapF on respiratory quotient (RQ) at rest and at one hour following the maximal exercise for three groups (Placebo, CapF 100 and CapF 200). The violin plot outlines demonstrate kernel probability density. The width of the shaded area shows the distribution of the data. The thick dotted line shows the median, and thin dotted lines represent quartiles. (A) Treatment Vs time of RQ before exercise showed significant reduction at doses of 100 mg/day (P < 0.001) and 200 mg/day (P < 0.001) respectively at the end of study. The percentage of reduction were 4.2 and 11.45% respectively; (B) Treatment Vs time of RQ after exercise showed significant reduction at doses of 100 mg/day (P < 0.001) and 200 mg/day (P < 0.001) are spectively. The values are expressed as mean \pm SD. (C) Percentage difference based on baseline values for Placebo, CapF 100 and CapF 200. The symbol *** in the bar diagram indicate significant difference at P < 0.05 compared to placebo.



FIGURE 5

(A) Violin plot showing the acute and chronic effects of CapF on the time to exhaustion at rest and at one hour following the maximal exercise for three groups (Placebo, CapF 100, and CapF 200). The violin plot outlines demonstrate kernel probability density. The width of the shaded area shows the distribution of the data. The thick dotted line shows the median, and thin dotted lines represent quartiles. The results revealed significant increase in time of exhaustion compared to baseline upon supplementation with CapF 100 and CapF 200 (P < 0.001). The increase in CapF 100 is 68.52% (P < 0.001) and that of CapF 200 is 56.13% (P < 0.001). No significant change was observed in placebo (P > 0.05). (B) Percentage difference based on baseline values for Placebo, CapF 100 and CapF 200. The symbol "*" in the bar diagram indicate significant difference at P < 0.05 compared to placebo.